{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:21:26Z","timestamp":1786119686750,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1097\/coc.0b013e3181fe46a1","type":"journal-article","created":{"date-parts":[[2011,1,7]],"date-time":"2011-01-07T03:06:45Z","timestamp":1294369605000},"page":"581-586","source":"Crossref","is-referenced-by-count":14,"title":["Dual Blockade of the EGFR and COX-2 Pathways"],"prefix":"10.1097","volume":"34","author":[{"given":"Emily","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"LaFleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mace L.","family":"Rothenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nipun","family":"Merchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert Craig","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakula","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine H.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan D.","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210128","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/00001813-200506000-00003","article-title":"Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy.","volume":"16","author":"Pal","year":"2005","journal-title":"Anticancer Drugs"},{"key":"R2-5-20210128","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1158\/1078-0432.CCR-07-1216","article-title":"TACEADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer.","volume":"14","author":"Merchant","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R3-5-20210128","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"R4-5-20210128","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1200\/JCO.2005.09.051","article-title":"COX-2: a molecular target for colorectal cancer prevention.","volume":"23","author":"Brown","year":"2005","journal-title":"J Clin Oncol"},{"key":"R5-5-20210128","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1073\/pnas.94.7.3336","article-title":"Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.","volume":"94","author":"Tsujii","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R6-5-20210128","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0092-8674(00)81433-6","article-title":"Cyclooxygenase regulates angiogenesis induced by colon cancer cells.","volume":"93","author":"Tsujii","year":"1998","journal-title":"Cell"},{"key":"R7-5-20210128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2407-8-33","article-title":"Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polypadenoma.","volume":"8","author":"Kawasaki","year":"2008","journal-title":"BMC Cancer"},{"key":"R8-5-20210128","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2559.2003.01627.x","article-title":"Cyclooxygenase-2 is expressed frequently and early in Barretts oesophagus and associated adenocarcinoma.","volume":"43","author":"Lagorce","year":"2003","journal-title":"Histopathology"},{"key":"R9-5-20210128","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","article-title":"The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.","volume":"342","author":"Steinbach","year":"2000","journal-title":"N Engl J Med"},{"key":"R10-5-20210128","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1388-1981(99)00034-7","article-title":"Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells.","volume":"1438","author":"Kinoshita","year":"1999","journal-title":"Biochim Biophys"},{"key":"R11-5-20210128","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1158\/1078-0432.CCR-08-1627","article-title":"Dose-dependent increases in circulating TGF- and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.","volume":"15","author":"Mutsaers","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R12-5-20210128","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJM200012073432305","article-title":"Treatment of Menetriers disease with a monoclonal antibody against the epidermal growth factor receptor.","volume":"343","author":"Burdick","year":"2000","journal-title":"N Engl J Med"},{"key":"R13-5-20210128","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ab.2004.08.019","article-title":"Quantification of the major urinary metabolite of PGE2 by a liquid chromatographicmass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer.","volume":"334","author":"Murphey","year":"2004","journal-title":"Anal Biochem"},{"key":"R14-5-20210128","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1073\/pnas.0401294101","article-title":"Myristoylated Naked2 escorts transforming growth factor to the basolateral plasma membrane of polarized epithelial cells.","volume":"101","author":"Li","year":"2004","journal-title":"PNAS"},{"key":"R15-5-20210128","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/0003-2697(90)90043-9","article-title":"Determination of 11-hydroxy-9, 15-dioxo-2,3,4,5,20-pentanor-19-carboxyprostanoic acid and 9, 11 -dihyroxy-15-oxo-2,3,4,5,20-pentanor-19-carboxyprostanoic acid by gas chromatographynegative ion chemical ionization triple-stage quadrupole mass spectrometry.","volume":"189","author":"Schweer","year":"1990","journal-title":"Anal Biochem"},{"key":"R16-5-20210128","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose--1,3-galactose.","volume":"358","author":"Chung","year":"2008","journal-title":"N Engl J Med"},{"key":"R17-5-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New Guidelines to evaluate the response to treatment in solid tumors.","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R18-5-20210128","doi-asserted-by":"crossref","first-page":"9265","DOI":"10.1200\/JCO.2005.03.0536","article-title":"Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.","volume":"23","author":"Rothenberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"R20-5-20210128","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.","volume":"25","author":"Van Cutsem","year":"2006","journal-title":"J Clin Oncol"},{"key":"R21-5-20210128","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000087302","article-title":"A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.","volume":"69","author":"Pan","year":"2005","journal-title":"Oncology"},{"key":"R22-5-20210128","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00280-007-0472-1","article-title":"Phase II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.","volume":"61","author":"El-Rayes","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"suppl 7","key":"R23-5-20210128","doi-asserted-by":"crossref","first-page":"vii55","DOI":"10.1093\/annonc\/mdl952","article-title":"FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dellItalia Meridionale (GOIM).","volume":"17","author":"Maiello","year":"2006","journal-title":"Ann Oncol"},{"key":"R24-5-20210128","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdm544","article-title":"Irinotecan combined with infusional 5-fluorouracilfolinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.","volume":"19","author":"Kohne","year":"2008","journal-title":"Ann Oncol"},{"key":"R25-5-20210128","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.3748\/wjg.v13.i13.1947","article-title":"Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells.","volume":"13","author":"Lim","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R26-5-20210128","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1200\/JCO.2007.11.7812","article-title":"High incidence of Cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.","volume":"25","author":"ONeil","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000421-201112000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:55:53Z","timestamp":1786042553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000421-201112000-00005"}},"subtitle":["A Phase II Trial of Cetuximab and Celecoxib in Patients With Chemotherapy Refractory Metastatic Colorectal Cancer"],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e3181fe46a1","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}